SG10201804326SA - Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor - Google Patents
Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitorInfo
- Publication number
- SG10201804326SA SG10201804326SA SG10201804326SA SG10201804326SA SG10201804326SA SG 10201804326S A SG10201804326S A SG 10201804326SA SG 10201804326S A SG10201804326S A SG 10201804326SA SG 10201804326S A SG10201804326S A SG 10201804326SA SG 10201804326S A SG10201804326S A SG 10201804326SA
- Authority
- SG
- Singapore
- Prior art keywords
- mediated rejection
- methods
- organ transplant
- transplant patients
- esterase inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
METHODSOF TREATING ANTIBODY-MEDIATED REJECTION IN ORGAN TRANSPLANT PATIENTS WITH Cl-ESTERASE INHIBITOR A method and composition for treating or preventing antibody-mediated rejection (AMR) of a transplanted organ are provided. Figure 33
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907550P | 2013-11-22 | 2013-11-22 | |
| US201462029086P | 2014-07-25 | 2014-07-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201804326SA true SG10201804326SA (en) | 2018-06-28 |
Family
ID=52016153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201804326SA SG10201804326SA (en) | 2013-11-22 | 2014-11-21 | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9895428B2 (en) |
| EP (3) | EP4162947A1 (en) |
| JP (5) | JP6431912B2 (en) |
| KR (2) | KR102312817B1 (en) |
| CN (2) | CN105744949A (en) |
| AU (2) | AU2014352846B2 (en) |
| BR (1) | BR112016011499A2 (en) |
| CA (1) | CA2930964A1 (en) |
| CY (1) | CY1121298T1 (en) |
| DK (1) | DK3071219T3 (en) |
| ES (1) | ES2708655T3 (en) |
| HR (1) | HRP20190184T1 (en) |
| HU (1) | HUE041809T2 (en) |
| LT (1) | LT3071219T (en) |
| ME (1) | ME03318B (en) |
| MX (2) | MX378834B (en) |
| NZ (2) | NZ719724A (en) |
| PL (1) | PL3071219T3 (en) |
| PT (1) | PT3071219T (en) |
| RS (1) | RS58343B1 (en) |
| SG (1) | SG10201804326SA (en) |
| SI (1) | SI3071219T1 (en) |
| SM (1) | SMT201900042T1 (en) |
| WO (1) | WO2015077543A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4162947A1 (en) | 2013-11-22 | 2023-04-12 | Takeda Pharmaceutical Company Limited | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
| IL273185B2 (en) | 2017-09-15 | 2024-10-01 | Cedars Sinai Medical Center | C1 esterase inhibitors for use in improving tissue function in uterine transplantation in patients |
| WO2019166572A1 (en) * | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor |
| KR20210106521A (en) * | 2018-12-20 | 2021-08-30 | 세다르스-신나이 메디칼 센터 | Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplants |
| EP4010010A4 (en) * | 2019-08-08 | 2023-08-09 | Cedars-Sinai Medical Center | Methods of improving organ function |
| EP3895726A1 (en) | 2020-04-17 | 2021-10-20 | Pharming Intellectual Property BV | Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress |
| WO2022109124A1 (en) * | 2020-11-20 | 2022-05-27 | Csl Behring Gmbh | Method for treating antibody-mediated rejection |
| CN113035369B (en) * | 2021-03-10 | 2021-12-03 | 浙江大学 | Construction method of kidney transplantation anti-infective drug dosage prediction model |
| EP4366761A1 (en) | 2021-07-09 | 2024-05-15 | Pharming Intellectual Property B.V. | Using c1 esterase inhibitor to treat viral infection-related symptoms |
| WO2024152030A1 (en) * | 2023-01-13 | 2024-07-18 | The Uab Research Foundation | Crossmatching for porcine xenotransplantation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4212278B2 (en) * | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | Graft rejection inhibitor |
| DE10112617A1 (en) | 2001-03-14 | 2002-10-02 | Aventis Behring Gmbh | Use of a C1 esterase inhibitor to prevent or delay xenograft rejection in mammals |
| CA2654446C (en) | 2005-06-07 | 2014-02-25 | The Regents Of The University Of Colorado | Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival |
| JP5722524B2 (en) * | 2006-03-02 | 2015-05-20 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | Prolonging allograft survival by inhibiting complement activity |
| KR101956585B1 (en) * | 2011-09-24 | 2019-03-11 | 체에스엘 베링 게엠베하 | Combination therapy using immunoglobulin and c1-inhibitor |
| CN105188750A (en) * | 2013-03-08 | 2015-12-23 | 德国杰特贝林生物制品有限公司 | Treatment and prevention of remote ischemia-reperfusion injury |
| RS58351B1 (en) | 2013-03-15 | 2019-03-29 | Shire Viropharma Inc | C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency |
| EP4162947A1 (en) * | 2013-11-22 | 2023-04-12 | Takeda Pharmaceutical Company Limited | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
-
2014
- 2014-11-21 EP EP22188379.6A patent/EP4162947A1/en not_active Withdrawn
- 2014-11-21 RS RS20190148A patent/RS58343B1/en unknown
- 2014-11-21 NZ NZ719724A patent/NZ719724A/en unknown
- 2014-11-21 PT PT14809567T patent/PT3071219T/en unknown
- 2014-11-21 CN CN201480063697.5A patent/CN105744949A/en active Pending
- 2014-11-21 MX MX2016006656A patent/MX378834B/en unknown
- 2014-11-21 KR KR1020167013463A patent/KR102312817B1/en active Active
- 2014-11-21 EP EP14809567.2A patent/EP3071219B1/en not_active Revoked
- 2014-11-21 US US14/550,075 patent/US9895428B2/en active Active
- 2014-11-21 JP JP2016532586A patent/JP6431912B2/en active Active
- 2014-11-21 ME MEP-2019-31A patent/ME03318B/en unknown
- 2014-11-21 SI SI201431066T patent/SI3071219T1/en unknown
- 2014-11-21 ES ES14809567T patent/ES2708655T3/en active Active
- 2014-11-21 WO PCT/US2014/066784 patent/WO2015077543A1/en not_active Ceased
- 2014-11-21 KR KR1020217032180A patent/KR102384814B1/en active Active
- 2014-11-21 SM SM20190042T patent/SMT201900042T1/en unknown
- 2014-11-21 AU AU2014352846A patent/AU2014352846B2/en active Active
- 2014-11-21 EP EP18205998.0A patent/EP3494988B1/en active Active
- 2014-11-21 CN CN202010018792.0A patent/CN111388655A/en active Pending
- 2014-11-21 SG SG10201804326SA patent/SG10201804326SA/en unknown
- 2014-11-21 LT LTEP14809567.2T patent/LT3071219T/en unknown
- 2014-11-21 PL PL14809567T patent/PL3071219T3/en unknown
- 2014-11-21 BR BR112016011499-0A patent/BR112016011499A2/en not_active Application Discontinuation
- 2014-11-21 HU HUE14809567A patent/HUE041809T2/en unknown
- 2014-11-21 DK DK14809567.2T patent/DK3071219T3/en active
- 2014-11-21 HR HRP20190184TT patent/HRP20190184T1/en unknown
- 2014-11-21 CA CA2930964A patent/CA2930964A1/en not_active Abandoned
- 2014-11-21 NZ NZ759187A patent/NZ759187A/en unknown
-
2016
- 2016-05-20 MX MX2021000332A patent/MX2021000332A/en unknown
-
2017
- 2017-12-18 US US15/844,850 patent/US20180104319A1/en not_active Abandoned
-
2018
- 2018-10-15 JP JP2018194167A patent/JP6620206B2/en active Active
- 2018-11-15 JP JP2018214342A patent/JP2019023233A/en not_active Withdrawn
-
2019
- 2019-01-29 CY CY20191100119T patent/CY1121298T1/en unknown
-
2020
- 2020-01-02 AU AU2020200015A patent/AU2020200015B2/en active Active
- 2020-08-03 US US16/983,998 patent/US20200360495A1/en not_active Abandoned
-
2021
- 2021-01-29 JP JP2021012833A patent/JP2021063141A/en not_active Withdrawn
-
2022
- 2022-10-11 JP JP2022163044A patent/JP2022179637A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201804326SA (en) | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor | |
| IL285631A (en) | Methods for producing autologous t cells useful for cancer treatment and compositions thereof | |
| NZ709635A (en) | Bcl-2bcl-xl inhibitors and therapeutic methods using the same | |
| MX2021013665A (en) | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema. | |
| CL2007003622A1 (en) | Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method. | |
| DK2970867T3 (en) | PLANT GROWTH PROMOTIONAL BACTERIA AND APPLICATION METHODS | |
| CL2014001162A1 (en) | Microbial inoculants comprising lactobacillus; fertilizer composition comprising the same; method to increase plant growth and / or productivity. | |
| GB2538178A (en) | Viscosifier polymer for treatment of a subterranean formation | |
| AR093310A1 (en) | COMPOSITIONS AND METHODS TO IMPROVE GROWTH OF PLANTS | |
| PH12015500694A1 (en) | Compositions and methods for enhancing plant growth | |
| MX2015013622A (en) | Compositions and methods for enhancing plant growth. | |
| EP3458099A4 (en) | COMPOSITIONS AND METHODS FOR TREATING ACNE VULGARIS | |
| NZ703411A (en) | Use of markers in the diagnosis and treatment of prostate cancer | |
| EP3138399A4 (en) | Composition for organ, tissue, or cell transplantation, kit, and transplantation method | |
| MX342676B (en) | Humanised anti-cd52 antibodies. | |
| MX366208B (en) | Transformation of duckweed and uses thereof. | |
| EP3609312A4 (en) | PLANT GROWTH MEDIA AND METHOD FOR PRODUCING THEREOF | |
| MX2015012681A (en) | Compositions and methods for treating fungal and bacterial pathogens. | |
| EP2408804A4 (en) | VACCINATE COMPOSITIONS AND METHODS FOR TREATING MUCORMYCOSIS AND OTHER FUNGUS DISEASES | |
| TW201611841A (en) | Method for treatment of prostatic hyperplasia and/or ameliorating urinary disturbance with banana flower extract | |
| MX2014013049A (en) | Compositions and methods for heparan sulfate as a biomarker for transplant rejection. | |
| EP3064576A4 (en) | POLYPEPTIDE COMPOSITION AND METHOD FOR CULTURING PLURIPOTENT STEM CELLS USING THE SAME | |
| IN2015DN03329A (en) | ||
| IL273185A (en) | C1 esterase inhibitors for use in improving organ function in organ transplantation subjects | |
| MX2017007297A (en) | COMPOSITIONS AND METHODS FOR INTRODUCTION OF MICRONUTRIENTS. |